Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Potential nanoparticle treatment for macular degeneration and retinitis pigmentosa

Potential nanoparticle treatment for macular degeneration and retinitis pigmentosa

King's College London submits first clinical grade xeno-free hES cell lines to the UKSCB

King's College London submits first clinical grade xeno-free hES cell lines to the UKSCB

Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Regeneron’s Eylea for treating age related macular degeneration gets FDA nod

Regeneron’s Eylea for treating age related macular degeneration gets FDA nod

FDA approves EYLEA for treatment of wet Age-related Macular Degeneration

FDA approves EYLEA for treatment of wet Age-related Macular Degeneration

Regeneron receives FDA approval for Eylea to treat wet AMD

Regeneron receives FDA approval for Eylea to treat wet AMD

New protein in the fruit fly eye may shed light on neurodegenerative diseases

New protein in the fruit fly eye may shed light on neurodegenerative diseases

Lower glycemic index diet may delay onset of AMD-like lesions

Lower glycemic index diet may delay onset of AMD-like lesions

AHAF: Requests for ADR research grants increase by 33% this year

AHAF: Requests for ADR research grants increase by 33% this year

Low-grade inflammatory processes drive development of osteoarthritis

Low-grade inflammatory processes drive development of osteoarthritis

Promedior's Pentraxin-2 effectively suppresses liver fibrosis

Promedior's Pentraxin-2 effectively suppresses liver fibrosis

Macular degeneration drug may cause increased IOP

Macular degeneration drug may cause increased IOP

Zeaxanthin reduces risk for AMD

Zeaxanthin reduces risk for AMD

Mesoblast cleared to begin first phase 2 clinical trial for wet AMD

Mesoblast cleared to begin first phase 2 clinical trial for wet AMD

Mesoblast receives Singapore HSA regulatory clearance to begin wet AMD Phase 2 trial

Mesoblast receives Singapore HSA regulatory clearance to begin wet AMD Phase 2 trial

RetroSense, WSU sign license agreement for channelrhodopsin-based approaches

RetroSense, WSU sign license agreement for channelrhodopsin-based approaches

FDA approves Oxford BioMedica's UshStat IND to treat Usher syndrome type 1B

FDA approves Oxford BioMedica's UshStat IND to treat Usher syndrome type 1B

British scientist wins NYSCF - Robertson Stem Cell Prize

British scientist wins NYSCF - Robertson Stem Cell Prize

Study: Emerging pharmaceutical platform may produce undesirable effects on eye function

Study: Emerging pharmaceutical platform may produce undesirable effects on eye function

X-BODY, TRL enter collaboration to identify therapeutic target epitopes

X-BODY, TRL enter collaboration to identify therapeutic target epitopes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.